Studies found that improving the conversion rate of atrial fibrillation and maintaining sinus rhythm was the key after rheumatic heart disease associated valve replacement.12,13 Amiodarone which is the third class of
antiarrhythmic drug is a [beta] and [alpha] adrenergic receptor inhibitor.
(NASDAQ: CORV) (TSX: CORV), a specialty pharmaceutical company focused on commercializing hospital drugs, today announced that an abstract highlighting the results of the SPECTRUM study evaluating Brinavess(vernakalant hydrochloride, IV), the Company's
antiarrhythmic drug for the rapid conversion of recent onset atrial fibrillation (AF), was selected for a poster presentation at the European Society of Cardiology (ESC) 2019 Congress taking place August 31 - September 4, 2019, in Paris.
The results from a 10-year randomized trial known as the CABANA trial (Catheter Ablation versus
Antiarrhythmic Drug trial for Atrial Fibrillation) have recently been released.
According to the company, Brinavess (vernakalant HCl, IV) is an
antiarrhythmic drug that acts preferentially in the atria by prolonging atrial refractoriness and slowing impulse conduction in a rate-dependent fashion.
Initiation of anticoagulation treatment started in 4.0% of the entire screened group, compared with 1.9% of the controls, The screened people also had a 0.9% rate of receiving a pacemaker or defibrillator, a 0.8% rate of starting on treatment with an
antiarrhythmic drug, and a 0.3% rate of undergoing catheter ablation, compared with none, 0.3%, and one of the controls, respectively, said Dr.
This poster presentation highlights reduced hospitalization in patients treated with Brinavess, Correvio's
antiarrhythmic drug for the rapid conversion of recent onset atrial fibrillation, from a clinical survey assessing patients with acute AF at the Hillel Yaffe Medical Center located in Hadera, Israel.
BOSTON -- Ablation of atrial fibrillation led to significantly better quality of life improvements, compared with
antiarrhythmic drug therapy, in a prespecified, secondary analysis of data from the CABANA multicenter, randomized trial with 2,204 patients.
Cardiology department did not suggest any
antiarrhythmic drug, but cardiac enzymes, ECG follow-up, and low molecular weight heparin application were suggested.
Risk of atrial fibrillation after atrial flutter ablation: impact of AF history, gender, and
antiarrhythmic drug medication.
In the current study, the effect of SSYX capsule has been tested in an animal study and it was also indicated by randomized double-blinded, positive drug-controlled clinical trials.[2] However, the working mechanism of SSYX capsule as
antiarrhythmic drug is not completely clear yet.[3],[4] This study tried to investigate the effect of SSYX capsule on the myocardial electrophysiology of acute AF dog model.
Propafenone (Rythmol, Abbott, Chicago, IL, USA) is a group 1C
antiarrhythmic drug that has sodium channel-blocking effects.
Therefore, we chose
antiarrhythmic drug therapy, indicated in subjects with syncope due to rapid AF (Ic) [4].
antiarrhythmic drug - a drug used to treat an abnormal heart rhythm